Mark C Kelley

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4879406/publications.pdf

Version: 2024-02-01

19	1,569	567281 15	794594 19
papers	citations	h-index	g-index

19	19	19	2517
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. Nature Nanotechnology, 2019, 14, 269-278.	31.5	406
2	Development of a spatially offset Raman spectroscopy probe for breast tumor surgical margin evaluation. Journal of Biomedical Optics, 2011, 16, 077006.	2.6	162
3	Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. Immunotherapy, 2015, 7, 611-619.	2.0	141
4	Accuracy of Intraoperative Gross Examination of Surgical Margin Status in Women Undergoing Partial Mastectomy for Breast Malignancy. American Surgeon, 2005, 71, 22-28.	0.8	120
5	Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy. Cancer Immunology Research, 2013, 1, 373-377.	3.4	100
6	Lymphatic mapping and sentinel lymphadenectomy for breast cancer. American Journal of Surgery, 2004, 188, 49-61.	1.8	99
7	Autofluorescence and diffuse reflectance spectroscopy and spectral imaging for breast surgical margin analysis. Lasers in Surgery and Medicine, 2010, 42, 15-23.	2.1	92
8	Accuracy of intraoperative gross examination of surgical margin status in women undergoing partial mastectomy for breast malignancy. American Surgeon, 2005, 71, 22-7; discussion 27-8.	0.8	92
9	Mdm2 and Aurora Kinase A Inhibitors Synergize to Block Melanoma Growth by Driving Apoptosis and Immune Clearance of Tumor Cells. Cancer Research, 2015, 75, 181-193.	0.9	76
10	Comparison of autofluorescence, diffuse reflectance, and Raman spectroscopy for breast tissue discrimination. Journal of Biomedical Optics, 2008, 13, 054009.	2.6	68
11	Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment. Journal of the National Cancer Institute, 2016, 108, djv406.	6.3	61
12	Evaluating feasibility of an automated 3-dimensional scanner using Raman spectroscopy for intraoperative breast margin assessment. Scientific Reports, 2017, 7, 13548.	3.3	45
13	Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types. Cancer Immunology Research, 2019, 7, 86-99.	3.4	27
14	Preliminary Results from a Prospective Trial of Preoperative Combined BRAF and MEK-Targeted Therapy in Advanced BRAF Mutation-Positive Melanoma. Journal of the American College of Surgeons, 2015, 220, 581-593e1.	0.5	26
15	Metastatic Melanoma Patientâ€“Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. Clinical Cancer Research, 2020, 26, 3803-3818.	7.0	21
16	ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. Oncotarget, 2015, 6, 22348-22360.	1.8	12
17	A phase <scp>II</scp> trial of erlotinib and bevacizumab for patients with metastatic melanoma. Pigment Cell and Melanoma Research, 2016, 29, 101-103.	3.3	11
18	<scp>BRAF</scp> and <scp>MEK</scp> inhibitor therapy eliminates Nestinâ€expressing melanoma cells in human tumors. Pigment Cell and Melanoma Research, 2018, 31, 708-719.	3.3	9

#	Article	IF	Citations
19	Long-termÂcure after complete resection and adjuvant immunotherapy for distant melanoma metastases.. Journal of Clinical Oncology, 2012, 30, 8534-8534.	1.6	1